Wednesday - December 25, 2024
Goodwin Advised Nuvig Therapeutics on $161 Million Series B Financing, Progression to Phase 2 Development With Novel, Second-Generation Immunomodulator
December 06, 2024
BOSTON, Massachusetts, Dec. 6 -- Goodwin, a law firm, issued the following news release:

The Life Sciences team advised Nuvig Therapeutics, Inc., ("Nuvig") on the closing of a $161 million Series B financing co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products